Cytyc Gets Digene After Long Courtship, On Verge Of New Indication
This article was originally published in The Gray Sheet
Executive Summary
The payback on Cytyc's $554 mil. acquisition of Digene could get a quick boost from Digene's pending primary screening indication for DNA Pap for cervical cancer